The discovery that OCA causes severe side effects including pruritus (up to 70% of subjects with primary biliary cholangitis, PBC), and acute liver decompensation in cirrhotic patients [5], has raised concerns over the safety of FXR agonism in the treatment of severe liver diseases. The gene discussed is NR1H4; the disease is primary biliary cholangitis.